NCT00485108

Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty

Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty (SLT): A Randomized, Masked, Placebo Controlled Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: Queen's University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The type of anti-inflammatory medication used post selective laser trabeculoplasty (SLT) may have an impact on the intra-ocular pressure (IOP) lowering effect of SLT. This study will evaluate the IOP lowering effect of SLT following the topical administration of one of the following: prednisolone 1%, ketorolac 0.5% or artificial tears.

Detailed description

Patients who have been chosen to undergo SLT for glaucoma will be randomized to receive one of prednisolone 1%, ketorolac 0.5% or artificial tears four times a day for 5 days following administration of the laser treatment. The IOP will be measured at various time points following SLT: 1 hour, 2 days, 1 week, 1 month, 3 months, 6 months, and 1 year.

Conditions

• Primary Open Angle Glaucoma
• Pseudoexfoliation Glaucoma

Interventions

Type	Name	Description
DRUG	prednisolone 1%	eye drop once in each eye treated, 4 times / day for 5 days post-laser
DRUG	ketorolac 0.5%	eye drop once in each eye treated, 4 times / day for 5 days post-laser
DRUG	Artificial Tears (Methyl cellulose drops)	eye drop once in each eye treated, 4 times / day for 5 days post-laser

Timeline

• Start date: 2007-01-01
• Primary completion: 2009-06-01
• Completion: 2014-12-01
• First posted: 2007-06-12
• Last updated: 2015-09-23

Locations

1 site across 1 country: Canada